TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment Option Overview for ET
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 27, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Essential Thrombocythemia
Initiation of therapy for patients with asymptomatic ET is controversial.[18] In a case-controlled observational study of 65 low-risk patients (age <60 years, platelet count <1,500 × 109/L, and no history of thrombosis or hemorrhage) with a median follow-up of 4.1 years, the thrombotic risk of 1.91 cases per 100 patient-years and hemorrhagic risk of 1.12 cases per 100 patient-years was not increased compared with normal controls.[19]
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice